Literature DB >> 14703714

Metabolic drug interactions with new psychotropic agents.

Edoardo Spina1, Maria Gabriella Scordo, Concetta D'Arrigo.   

Abstract

New psychotropic drugs introduced in clinical practice in recent years include new antidepressants, such as selective serotonin reuptake inhibitors (SSRI) and 'third generation' antidepressants, and atypical antipsychotics, i.e. clozapine, risperidone, olanzapine, quetiapine, ziprasidone and amisulpride. These agents are extensively metabolized in the liver by cytochrome P450 (CYP) enzymes and are therefore susceptible to metabolically based drug interactions with other psychotropic medications or with compounds used for the treatment of concomitant somatic illnesses. New antidepressants differ in their potential for metabolic drug interactions. Fluoxetine and paroxetine are potent inhibitors of CYP2D6, fluvoxamine markedly inhibits CYP1A2 and CYP2C19, while nefazodone is a potent inhibitor of CYP3A4. These antidepressants may be involved in clinically significant interactions when coadministered with substrates of these isoforms, especially those with a narrow therapeutic index. Other new antidepressants including sertraline, citalopram, venlafaxine, mirtazapine and reboxetine are weak in vitro inhibitors of the different CYP isoforms and appear to have less propensity for important metabolic interactions. The new atypical antipsychotics do not affect significantly the activity of CYP isoenzymes and are not expected to impair the elimination of other medications. Conversely, coadministration of inhibitors or inducers of the CYP isoenzymes involved in metabolism of the various antipsychotic compounds may alter their plasma concentrations, possibly leading to clinically significant effects. The potential for metabolically based drug interactions of any new psychotropic agent may be anticipated on the basis of knowledge about the CYP enzymes responsible for its metabolism and about its effect on the activity of these enzymes. This information is essential for rational prescribing and may guide selection of an appropriate compound which is less likely to interact with already taken medication(s).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14703714     DOI: 10.1046/j.1472-8206.2003.00193.x

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  22 in total

Review 1.  Psychotic major depression: a benefit-risk assessment of treatment options.

Authors:  Audrey R Tyrka; Lawrence H Price; Marcelo F Mello; Andrea F Mello; Linda L Carpenter
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

2.  Toxic clozapine serum levels during acute urinary tract infection: a case report.

Authors:  Julia Jecel; Tanja M Michel; Lise Gutknecht; Daniela Schmidt; Bruno Pfuhlmann; Burkhard E Jabs
Journal:  Eur J Clin Pharmacol       Date:  2005-01-19       Impact factor: 2.953

3.  Profound weight loss associated with reboxetine use in a 44-year-old woman.

Authors:  T Y-T Lu; A Kupa; G Easterbrook; A A Mangoni
Journal:  Br J Clin Pharmacol       Date:  2005-08       Impact factor: 4.335

Review 4.  The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions.

Authors:  Abdo Haddad; Mellar Davis; Ruth Lagman
Journal:  Support Care Cancer       Date:  2006-12-01       Impact factor: 3.603

Review 5.  Review: Pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects.

Authors:  J L Pilgrim; D Gerostamoulos; Olaf H Drummer
Journal:  Forensic Sci Med Pathol       Date:  2010-11-04       Impact factor: 2.007

Review 6.  Pharmacogenetics of response to antipsychotics in patients with schizophrenia.

Authors:  Maria J Arranz; Margarita Rivera; Janet C Munro
Journal:  CNS Drugs       Date:  2011-11-01       Impact factor: 5.749

7.  Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination.

Authors:  Michael Poyurovsky; Camil Fuchs; Artashez Pashinian; Adva Levi; Ronit Weizman; Abraham Weizman
Journal:  Psychopharmacology (Berl)       Date:  2012-12-13       Impact factor: 4.530

8.  Population pharmacokinetic analysis of drug-drug interactions among risperidone, bupropion, and sertraline in CF1 mice.

Authors:  Jun-Sheng Wang; C Lindsay DeVane; B Bryan Gibson; Jennifer L Donovan; John S Markowitz; Hao-Jie Zhu
Journal:  Psychopharmacology (Berl)       Date:  2005-11-09       Impact factor: 4.530

9.  Moclobemide monotherapy vs. combined therapy with valproic acid or carbamazepine in depressive patients: a pharmacokinetic interaction study.

Authors:  Anita Rakic Ignjatovic; Branislava Miljkovic; Dejan Todorovic; Ivana Timotijevic; Milena Pokrajac
Journal:  Br J Clin Pharmacol       Date:  2008-12-05       Impact factor: 4.335

10.  Sequential multiple-assignment randomized trial design of neurobehavioral treatment for patients with metastatic malignant melanoma undergoing high-dose interferon-alpha therapy.

Authors:  S Freda Auyeung; Qi Long; Erica Bruce Royster; Smitha Murthy; Marcia D McNutt; David Lawson; Andrew Miller; Amita Manatunga; Dominique L Musselman
Journal:  Clin Trials       Date:  2009-09-28       Impact factor: 2.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.